-
European Journal of Heart Failure 05/2013; · 4.90 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Aims: Experience with transcatheter valve-in-valve implantation in a failing bioprosthetic tricuspid valve is very limited. Fewer than 30 cases have been reported, and in most of them the Melody valve (Medtronic, Inc., Minneapolis, MN, USA) was used. With this case report and review of literature we sought to evaluate the safety and feasibility of the Edwards SAPIEN transcatheter valve (Edwards Lifesciences, Irvine, CA, USA) in valve implantation in the tricuspid position and to compare this intervention with the more established Melody valve implantation. Methods and results: We describe one of the rarely reported Edwards SAPIEN valve implantations in a bioprosthetic tricuspid valve which is also the first in a patient with Ebstein's anomaly. A review is presented of all eight case reports on Edwards SAPIEN valve implantations in tricuspid position. The procedure was successful in all cases. Valve performance after implantation was good and no complications were described. In only one procedure pre-stenting was performed. Transatrial, transjugular and transfemoral approaches have been used. The results are comparable to those of the series about Melody valve-in-valve implantation in the tricuspid valve. Mid-term follow-up data are not yet available for both valves. Conclusions: Edwards SAPIEN valve implantation in tricuspid bioprosthetic valves is feasible and safe. Considering the available sizes of the Edwards SAPIEN valve, it may become the preferred prosthesis for valve-in-valve implantation in the tricuspid position in the future.
EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 09/2012; 8(5):628-33. · 3.29 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Current treatment for coronary stent thrombosis (ST) often lacks satisfactory results and clinical outcome is poor. We investigated the impact of manual thrombus aspiration during percutaneous coronary intervention (PCI) on myocardial reperfusion and clinical outcome in patients with angiographically proved ST. We interrogated our PCI registry for patients with a first stent placement from January 2002 through May 2010 who had undergone an emergency repeated PCI procedure and systematically reviewed coronary angiograms and hospital records for evidence of ST. We identified 113 patients with ST. Thrombus aspiration was used in 51 patients and 62 patients received conventional PCI. Histopathologic analysis of thrombus aspirates was performed in 6 patients. Use of thrombus aspiration predicted postprocedure Thrombolysis In Myocardial Infarction grade 3 flow (odds ratio 3.16, 95% confidence interval 1.22 to 8.17, p = 0.018) and myocardial blush grade 2/3 (odds ratio 3.20, 95% confidence interval 1.20 to 8.55, p = 0.020) after multivariable adjustment with bootstrap model selection. Distal embolization was lower in the thrombus aspiration group compared to the conventional PCI group (14% vs 37%, p = 0.017). In most patients, aspirated thrombus was large and contained platelet and erythrocyte components at histopathologic analysis. Mortality in the thrombus aspiration group and conventional PCI group was 9.8% versus 16% at 30 days (p = 0.351) and 12% versus 21% at 1 year (p = 0.220), respectively. In conclusion, use of manual thrombus aspiration in patients with ST was associated with greater epicardial and microvascular myocardial reperfusion. In addition, mortality was lower in patients treated with thrombus aspiration, although not statistically significant.
The American journal of cardiology 09/2011; 108(12):1721-7. · 3.58 Impact Factor
-
Youlan L Gu,
Adriaan A Voors,
Felix Zijlstra,
Hans L Hillege,
Joachim Struck,
Serge Masson,
Tarcisio Vago,
Stefan D Anker, Ad F M van den Heuvel,
Dirk J van Veldhuisen,
Bart J G L de Smet
[show abstract]
[hide abstract]
ABSTRACT: Early detection of acute myocardial infarction (AMI) using cardiac biomarkers of myocardial necrosis remains limited since these biomarkers do not rise within the first hours from onset of AMI. We aimed to compare the temporal release pattern of the C-terminal portion of provasopressin (copeptin) with conventional cardiac biomarkers, including creatine kinase isoenzyme (CK-MB), cardiac troponin T (cTnT), and high-sensitivity cTnT (hs-cTnT), in patients with ST-elevation AMI.
We included 145 patients undergoing successful primary percutaneous coronary intervention (PCI) for a first ST-elevation AMI presenting within 12 h of symptom onset. Blood samples were taken on admission and at four time points within the first 24 h after PCI.
In contrast to all other markers, copeptin levels were already elevated on admission and were higher with a shorter time from symptom onset to reperfusion and lower systolic blood pressure. Copeptin levels peaked immediately after symptom onset at a maximum of 249 pmol/L and normalized within 10 h. In contrast, CK-MB, cTnT, and hs-cTnT peaked after 14 h from symptom onset at a maximum of 275 U/L, 5.75 μg/L, and 4.16 μg/L, respectively, and decreased more gradually.
Copeptin has a distinct release pattern in patients with ST-elevation AMI, peaking within the first hour after symptom onset before conventional cardiac biomarkers and falling to normal ranges within the first day. Further studies are required to determine the exact role of copeptin in AMI suspects presenting within the first hours after symptom onset.
Clinical Research in Cardiology 07/2011; 100(12):1069-76. · 2.95 Impact Factor
-
Youlan L Gu,
Marthe A Kampinga,
Wouter G Wieringa,
Marieke L Fokkema,
Maarten W Nijsten,
Hans L Hillege, Ad F M van den Heuvel,
Eng-Shiong Tan,
Gabija Pundziute,
Rik van der Werf,
Siyrous Hoseyni Guyomi,
Iwan C C van der Horst,
Felix Zijlstra,
Bart J G L de Smet
[show abstract]
[hide abstract]
ABSTRACT: administration of the glycoprotein IIb/IIIa inhibitor abciximab is an effective adjunctive treatment strategy during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Although small-scale studies have suggested beneficial effects of intracoronary over intravenous administration of abciximab, this has not been investigated in a medium-scale randomized clinical trial.
a total of 534 ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with thrombus aspiration within 12 hours of symptom onset were randomized to either an intracoronary or an intravenous bolus of abciximab (0.25 mg/kg). Patients were pretreated with aspirin, heparin, and clopidogrel. The primary end point was the incidence of restored myocardial reperfusion, defined as complete ST-segment resolution. Secondary end points included myocardial reperfusion as assessed by myocardial blush grade, enzymatic infarct size, and major adverse cardiac events at 30 days. The incidence of complete ST-segment resolution was similar in the intracoronary and intravenous groups (64% versus 62%; P=0.562). However, the incidence of myocardial blush grade 2/3 was higher in the intracoronary group than in the intravenous group (76% versus 67%; P=0.022). Furthermore, enzymatic infarct size was smaller in the intracoronary than in the intravenous group (P=0.008). The incidence of major adverse cardiac events was similar in both groups (5.5% versus 6.1%; P=0.786).
in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with thrombus aspiration, intracoronary administration of abciximab compared with intravenous administration does not improve myocardial reperfusion as assessed by ST-segment resolution. However, intracoronary administration is associated with improved myocardial reperfusion as assessed by myocardial blush grade and a smaller enzymatic infarct size.
Circulation 12/2010; 122(25):2709-17. · 14.74 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Multiple trials have documented that myocardial blush grade (MBG) after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) has prognostic value for long-term clinical outcome. However, to the best of our knowledge, no study has determined the clinical use of MBG in routine clinical practice. We determined the prognostic value of MBG scored by the operator during primary PCI in consecutive patients with STEMI.
The prognostic value of MBG scored by the operator in relation to 1-year all cause mortality was evaluated in all patients with STEMI who underwent primary PCI between January 2004 and July 2008 in our hospital. The incidence of MBG 0, 1, 2, and 3 was 12%, 14%, 36%, and 38%, respectively, in 2118 consecutive patients with STEMI. Follow-up of all 2118 patients showed a 1-year all cause mortality rate of 8% (168 of 2118): 24%, 10%, 6%, and 4%, respectively, among patients with MBG 0, 1, 2, and 3 (P<0.001). In the 1763 patients with Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 after PCI, these mortality rates were 17%, 10%, 6%, and 4%, respectively (P<0.001). MBG scored by the operator was a strong independent predictor of 1-year all cause mortality corrected for other well-known predictive variables, including TIMI flow grade.
MBG scored by the operator during primary PCI has prognostic value for 1-year all cause mortality in patients with STEMI in routine clinical practice. Therefore, the MBG should be documented, in addition to the TIMI flow grade, during primary PCI in patients with STEMI in standard PCI reports in routine clinical practice.
Circulation Cardiovascular Interventions 06/2010; 3(3):216-23. · 6.06 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In patients with heart failure (HF), statin treatment might improve myocardial perfusion, but could also have detrimental effects on myocardial metabolism. A predefined substudy of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial sought to determine the effects of statin treatment on myocardial blood flow reserve and cardiac metabolism. Sixteen patients with HF (New York Heart Association class II or III) were randomized to rosuvastatin 10 mg/day (n = 8) or placebo treatment (n = 8). At baseline and after 6 months of treatment, nitrogen-13 ammonia at rest and after dipyridamole stress and 18-fluorodeoxyglucose positron emission tomography were performed. Rosuvastatin treatment significantly lowered total (-36%, p <0.01) and low-density lipoprotein (-47%, p <0.001) cholesterol and C-reactive protein levels (-36%, p <0.05). Myocardial perfusion reserve (ratio) changed from 1.64 +/- 0.90 to 1.30 +/- 0.37 in placebo-treated and from 1.51 +/- 0.18 to 1.55 +/- 0.34 in rosuvastatin-treated patients (p = NS). Metabolic mismatch changed from 4.25 +/- 2.37% to 4.38 +/- 3.81% in placebo-treated and from 5.13 +/- 2.75% to 3.50 +/- 2.73% in rosuvastatin-treated patients (p = NS). In conclusion, changes regarding myocardial perfusion and metabolic mismatch after 6 months of rosuvastatin treatment in patients with HF did not suggest any beneficial or adverse effects in this pilot study, although due to the small numbers of patients small effects might have been missed.
The American journal of cardiology 02/2010; 105(4):517-21. · 3.58 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Due to the growing number of cardiac device implantations it is important to develop methods to reduce device-implantation related complications.
To determine whether a wound inspection clinic can play a role in the detection of device-implantation related complications.
Single-center observational study evaluating patients who received a pacemaker or implantable cardioverter-defibrillator (ICD).
Of 159 patients who received an appointment for the wound inspection clinic, 52 (33%) received a pacemaker and 107 (67%) received an ICD. The majority had no signs of infection. Pain (n = 13,8%) and swelling (n = 11,7%) were the most frequent signs observed, but they never necessitated intervention and recovered spontaneously in all patients. During follow-up (mean 20+/-9 weeks), complications occurred in 10 patients (6%). Most complications occurred early, within 4 days after implantation. The two late complications (at 19 and 41 days) could not be recognized at the wound inspection clinic.
We found no useful role for a wound inspection clinic two weeks post-implant to detect device-related complications. Open rapid access to the pacemaker/ICD center for patients with signs and symptoms of (threatening) complications seems to be more appropriate to manage post-implant patients.
European journal of cardiovascular nursing: journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology 04/2009; 8(4):288-92.
-
Pieter J Vlaar,
Tone Svilaas,
Iwan C van der Horst,
Gilles F H Diercks,
Marieke L Fokkema,
Bart J G L de Smet, Ad F M van den Heuvel,
Rutger L Anthonio,
Gillian A Jessurun,
Eng-Shiong Tan,
Albert J H Suurmeijer,
Felix Zijlstra
[show abstract]
[hide abstract]
ABSTRACT: Percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction can be complicated by spontaneous or angioplasty-induced embolisation of atherothrombotic material. Distal blockage induces microvascular obstruction and can result in less than optimum reperfusion of viable myocardium. The Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS) found that thrombus aspiration resulted in improved myocardial reperfusion compared with conventional PCI, but whether this benefit improves clinical outcome is unknown. We aimed to investigate whether the early efficacy of thrombus aspiration seen in TAPAS translated into clinical benefit after 1 year.
Patients with ST-elevation myocardial infarction enrolled at the University Medical Centre Groningen were randomly assigned in a 1:1 ratio to either thrombus aspiration or conventional treatment, before undergoing initial coronary angiography. Exclusion criteria were rescue PCI after thrombolysis and known existence of a concomitant disease with life expectancy less than 6 months. Of the 1071 patients enrolled between January, 2005, and December, 2006, vital status at or beyond 1 year after randomisation was available for 1060 (99%). The primary endpoint was cardiac death or non-fatal reinfarction after 1 year, and analysis was by intention to treat. The TAPAS trial is registered with Current Controlled Trials number ISRCTN16716833.
Cardiac death at 1 year was 3.6% (19 of 535 patients) in the thrombus aspiration group and 6.7% (36 of 536) in the conventional PCI group (hazard ratio [HR] 1.93; 95% CI 1.11-3.37; p=0.020). 1-year cardiac death or non-fatal reinfarction occurred in 5.6% (30 of 535) of patients in the thrombus aspiration group and 9.9% (53 of 536) of patients in the conventional PCI group (HR 1.81; 95% CI 1.16-2.84; p=0.009).
Compared with conventional PCI, thrombus aspiration before stenting of the infarcted artery seems to improve the 1-year clinical outcome after PCI for ST-elevation myocardial infarction.
The Lancet 07/2008; 371(9628):1915-20. · 38.28 Impact Factor
-
Tone Svilaas,
Pieter J Vlaar,
Iwan C van der Horst,
Gilles F H Diercks,
Bart J G L de Smet, Ad F M van den Heuvel,
Rutger L Anthonio,
Gillian A Jessurun,
Eng-Shiong Tan,
Albert J H Suurmeijer,
Felix Zijlstra
[show abstract]
[hide abstract]
ABSTRACT: Primary percutaneous coronary intervention (PCI) is effective in opening the infarct-related artery in patients with myocardial infarction with ST-segment elevation. However, the embolization of atherothrombotic debris induces microvascular obstruction and diminishes myocardial reperfusion.
We performed a randomized trial assessing whether manual aspiration was superior to conventional treatment during primary PCI. A total of 1071 patients were randomly assigned to the thrombus-aspiration group or the conventional-PCI group before undergoing coronary angiography. Aspiration was considered to be successful if there was histopathological evidence of atherothrombotic material. We assessed angiographic and electrocardiographic signs of myocardial reperfusion, as well as clinical outcome. The primary end point was a myocardial blush grade of 0 or 1 (defined as absent or minimal myocardial reperfusion, respectively).
A myocardial blush grade of 0 or 1 occurred in 17.1% of the patients in the thrombus-aspiration group and in 26.3% of those in the conventional-PCI group (P<0.001). Complete resolution of ST-segment elevation occurred in 56.6% and 44.2% of patients, respectively (P<0.001). The benefit did not show heterogeneity among the baseline levels of the prespecified covariates. At 30 days, the rate of death in patients with a myocardial blush grade of 0 or 1, 2, and 3 was 5.2%, 2.9%, and 1.0%, respectively (P=0.003), and the rate of adverse events was 14.1%, 8.8%, and 4.2%, respectively (P<0.001). Histopathological examination confirmed successful aspiration in 72.9% of patients.
Thrombus aspiration is applicable in a large majority of patients with myocardial infarction with ST-segment elevation, and it results in better reperfusion and clinical outcomes than conventional PCI, irrespective of clinical and angiographic characteristics at baseline. (Current Controlled Trials number, ISRCTN16716833.)
New England Journal of Medicine 03/2008; 358(6):557-67. · 53.30 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate the incidence and angiographic predictors of functional collateral perfusion in patients with stable coronary artery disease, scheduled for elective PCI.
Functional collateral perfusion is defined as a Pw/Pa ratio>or=0.24. Since this can only be measured intracoronary, it is important to investigate baseline clinical and angiographic predictors for functional collateral perfusion.
Collateral perfusion was measured during balloon inflation, with the use of a pressure-monitoring guide wire. Baseline clinical and angiographic characteristics were analyzed and collateral grading was done according to Rentrop's classification for coronary angiograms.
Functional collateral perfusion was found in 40 of the 89 patients (45%). Angiographic signs of collaterals (Rentrop>or=1) were present in 15 of the 89 patients. Of the 40 patients with the functional collateral perfusion 11 patients (28%) had Rentrop>or=1; of the 49 patients without functional collaterals there were 4 patients with Rentrop>or=1 (8%) (P=0.02). There were no significant differences in baseline clinical characteristics or in other angiographic characteristics.
In patients with stable coronary artery disease scheduled for elective PCI, 45% have functional collaterals. Rentrop's angiographic classification can be used to predict the presence or absence of functional collaterals, however with a rather modest positive and negative predictive value.
Catheterization and Cardiovascular Interventions 09/2007; 70(2):197-202. · 2.29 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Objectives: To investigate the incidence and angiographic predictors of functional collateral perfusion in patients with stable coronary artery disease, scheduled for elective PCI. Background: Functional collateral perfusion is defined as a Pw/Pa ratio ≥0.24. Since this can only be measured intracoronary, it is important to investigate baseline clinical and angiographic predictors for functional collateral perfusion. Methods: Collateral perfusion was measured during balloon inflation, with the use of a pressure-monitoring guide wire. Baseline clinical and angiographic characteristics were analyzed and collateral grading was done according to Rentrop's classification for coronary angiograms. Results: Functional collateral perfusion was found in 40 of the 89 patients (45%). Angiographic signs of collaterals (Rentrop ≥ 1) were present in 15 of the 89 patients. Of the 40 patients with the functional collateral perfusion 11 patients (28%) had Rentrop ≥1; of the 49 patients without functional collaterals there were 4 patients with Rentrop ≥1 (8%) (P = 0.02). There were no significant differences in baseline clinical characteristics or in other angiographic characteristics. Conclusions: In patients with stable coronary artery disease scheduled for elective PCI, 45% have functional collaterals. Rentrop's angiographic classification can be used to predict the presence or absence of functional collaterals, however with a rather modest positive and negative predictive value. © 2007 Wiley-Liss, Inc.
Catheterization and Cardiovascular Interventions 05/2007; 70(2):197 - 202. · 2.29 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Electrical neurostimulation can be used to treat patients with refractory angina, it reduces angina and ischemia. Previous data have suggested that electrical neurostimulation may alleviate myocardial ischaemia through increased collateral perfusion. We investigated the effect of electrical neurostimulation on functional collateral perfusion, assessed by distal coronary pressure measurement during acute coronary occlusion. We sought to study the effect of electrical neurostimulation on collateral perfusion.
Sixty patients with stable angina and significant coronary artery disease planned for elective percutaneous coronary intervention were split in two groups. In all patients two balloon inflations of 60 seconds were performed, the first for balloon dilatation of the lesion (first episode), the second for stent delivery (second episode). The Pw/Pa ratio (wedge pressure/aortic pressure) was measured during both ischaemic episodes. Group 1 received 5 minutes of active neurostimulation before plus 1 minute during the first episode, group 2 received 5 minutes of active neurostimulation before plus 1 minute during the second episode.
In group 1 the Pw/Pa ratio decreased by 10 +/- 22% from 0.20 +/- 0.09 to 0.19 +/- 0.09 (p = 0.004) when electrical neurostimulation was deactivated. In group 2 the Pw/Pa ratio increased by 9 +/- 15% from 0.22 +/- 0.09 to 0.24 +/- 0.10 (p = 0.001) when electrical neurostimulation was activated.
Electrical neurostimulation induces a significant improvement in the Pw/Pa ratio during acute coronary occlusion.
BMC Cardiovascular Disorders 02/2007; 7:18. · 1.52 Impact Factor
-
Erik Lipsic,
Peter van der Meer,
Adriaan A Voors,
B Daan Westenbrink, Ad F M van den Heuvel,
Hetty C de Boer,
Anton J van Zonneveld,
Regien G Schoemaker,
Wiek H van Gilst,
Felix Zijlstra,
Dirk J van Veldhuisen
[show abstract]
[hide abstract]
ABSTRACT: Besides stimulating hematopoiesis, erythropoietin (EPO) protects against experimental ischemic injury in the heart. The present study evaluated the safety and tolerability of EPO treatment in non-anemic patients with acute myocardial infarction (MI).
In this single-center, investigator-initiated, prospective study, patients with a first acute MI were randomized to one bolus of 300 microg darbepoetin alfa or no additional medication before primary coronary intervention. Twenty-two patients (mean age 59 +/- 2 years) were included. In the darbepoetin group, serum EPO-levels increased to 130-270 times that of controls, within the first 24 h. After darbepoetin administration, only small and non-significant changes in hematocrit levels were observed, while endothelial progenitor cells (EPCs, CD34+/CD45-) were increased at 72 h (2.8 vs. 1.0 cells/microl in control group, p < 0.01). No adverse events were recorded during the 30-day follow-up. After 4 months, left ventricular ejection fraction was similar in the two groups (52 +/- 3% in darbepoetin vs. 48 +/- 5% in control group, p = NS).
Intravenous single high-dose darbepoetin alfa in acute MI is both safe and well tolerated. Darbepoetin treatment after MI stimulates EPCs mobilization. The results of this first pilot study support a larger scale clinical trial to establish efficacy of EPO administration in patients after acute MI.
Cardiovascular Drugs and Therapy 04/2006; 20(2):135-41. · 3.13 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In this study, we investigated whether adjunction of glucose-insulin-potassium (GIK) infusion to primary percutaneous coronary intervention (PCI) affects hemodynamics in patients with an acute myocardial infarction.
Hemodynamic measurements were performed in a subset of patients (n = 81) in the GIPS 2, starting immediately after PCI and continued for 12 hours.
Cardiac index values were stable in both groups. During the first measurements, diastolic pulmonary artery pressure and the pulmonary capillary wedge pressure (PCWP) were significantly higher in the non-GIK group (diastolic pulmonary artery pressure 15 +/- 5 vs 18 +/- 7 mm Hg, P = .028 and PCWP 14 +/- 6 vs 18 +/- 7 mm Hg, P = .030). There was a decrease in PCWP from 18 +/- 7 to 15 +/- 6 mm Hg in the non-GIK group during the first 6 hours, whereas the pressures remained at 14 +/- 6 mm Hg in the GIK group. This difference in pattern of change did not reach statistical significance in the analysis of the interaction of PCWP by GIK group (P = .065).
Glucose-insulin-potassium infusion as adjunctive therapy to PCI in patients with acute myocardial infarction, without overt signs of heart failure, did not negatively affect hemodynamics.
American heart journal 03/2006; 151(2):345-51. · 4.65 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The aim of this study was to evaluate the combination of a silicon carbide-coated stent with the periprocedural use of abciximab in patients with type B2/C lesions. The study was a prospective cohort study and was conducted at the University Medical Center of Groningen.
Elective percutaneous transluminal coronary angioplasty was performed in a total of 44 patients. All had lesions with type B2/C characteristics and most were relatively small, tortuous and calcified. The involved vessel segment was stented. Silicon carbide-coated stents were used in combination with periprocedural abciximab. The main outcome measures were cardiac death, target vessel revascularization, myocardial infarction, and cerebrovascular accident.
At 6 months of follow-up, only 4 patients had a major adverse cardiac event. Three patients had undergone target vessel revascularization and 1 patient had suffered from a cerebrovascular accident. Sixteen patients underwent re-angiography 6 months after the initial procedure. The average stenosis at 6 months was 15% with a minimal lumen diameter of 2.4 mm.
A 9% major adverse cardiac event rate and a 7% target vessel revascularization rate at 6 months in type B2/C lesions were recorded. Further investigation on the use of this specific treatment combination is warranted.
Italian heart journal: official journal of the Italian Federation of Cardiology 10/2004; 5(9):663-6.
-
The American Journal of Cardiology 03/2003; 91(4):497-500. · 3.37 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Myocardial blood flow (MBF) reserve is impaired in congestive heart failure (CHF), while fluorine-18-deoxyglucose (18FDG) uptake is relatively preserved. To determine whether this mismatch could be interpreted as ischemia, we performed dobutamine stress echocardiography (DSE).
12 males with coronary artery disease (CAD) and CHF were compared with 12 controls with similar CAD but normal left ventricular (LV) function. MBF in non-infarct-related artery areas was assessed using [(13)N]ammonia positron emission tomography (PET), at rest and after dipyridamole infusion and 18FDG uptake was determined. DSE was performed with doses up to 40 microg/kg per min.
In areas with non-stenotic arteries MBF reserve was more impaired in CHF patients (1.6+/-0.6 vs. 2.2+/-0.5; CHF versus normal LV, respectively, P<0.05). MBF reserve was related to LV ejection fraction (r=0.6, P<0.05) and wall stress (r=-0.72, P<0.05). PET showed mismatch in 4+/-1% of the myocardium in normal LV, compared to 26+/-26% in CHF (P<0.05), coinciding with more ischemic wall motion abnormalities on DSE (21 vs. 4%; CHF versus normal LV, respectively, P<0.05).
In CHF, mismatch was found in areas supplied by non-stenotic coronary arteries. Corresponding areas showed ischemic wall motions on DSE. These findings suggest that the condition of CHF may play a role in perpetuating myocardial failure by inducing myocardial ischemia. Follow-up studies to investigate the ischemia-CHF relationship in time would be needed.
Cardiovascular Research 07/2002; 55(1):97-103. · 6.06 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Myocardial blood flow (MBF) reserve is impaired in patients with symptomatic chronic heart failure. Whether this is already present in asymptomatic left ventricular (LV) dysfunction, and whether it is affected by angiotensin converting enzyme (ACE) inhibition, is unknown. We examined MBF in 20 patients with asymptomatic LV dysfunction and compared them to healthy volunteers. MBF (reserve) was assessed with positron emission tomography (PET) and N-13 ammonia at rest, during dipyridamole stress test (DST) and during cold pressor test (CPT). Further, in the LV-dysfunction group, we studied the effects of 3 months treatment with ACE inhibition with a second PET study. Patients were randomized double-blind to perindopril 4 mg daily or placebo. MBF at rest was similar in controls and patients. DST-induced MBF reserve, however, was decreased in patients vs. controls (1.71 0.2 vs. 2.62 0.5, respectively p < 0.05).="" also="" cpt-induced="" mbf="" was="" lower="" in="" patients="" (1.14="" ="" 0.06="" vs.="" 1.23="" ="" 0.03,="">p < 0.05).="" after="" 3="" months="" double-blind="" treatment,="" cpt-induced="" mbf="" decreased="" in="" the="" placebo="" group="" (from="" 1.12="" ="" 0.02="" to="" 0.93="" ="" 0.06),="" but="" was="" preserved="" in="" the="" perindopril="" group="" (from="" 1.16="" ="" 0.08="" to="" 1.14="" ="" 0.08="" shifts="" from="" baseline:="" –0.19="" ="" 0.05="" vs.="" –0.02="" ="" 0.07="" respectively="">p = 0.07). This was compatible with a trend to a smaller increase in coronary vascular resistance during CPT (1.23 0.08 vs. 1.03 0.06, placebo vs. perindopril, p = 0.06). In patients with asymptomatic LV dysfunction, MBF, both after vasodilation and after CPT, is already impaired. ACE inhibition with perindopril during this short-term treatment had no significant effects.
The International Journal of Cardiovascular Imaging 09/2001; 17(5):353-359. · 2.29 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: There is convincing evidence that (prolonged) episodes of myocardial ischemia lead to impairment of left ventricular (LV) function and ultimately to chronic congestive heart failure(CHF), but whether the opposite is also true has not been well established. We studied this issue in two groups of CHF patients with positron emission tomography (PET) by using [13N]ammonia (13NH3) as a tracer. In the first protocol we compared 12 patients with idiopathic dilated cardiomyopathy (who have normal coronary arteries) with 12 healthy controls. In the second protocol we studied a group of 24 patients with documented coronary artery disease (CAD). In this protocol, we compared patients with normal LV function to those with LV dysfunction and CHF. In patients with cardiomyopathy, myocardial blood flow at rest was normal but flow reserve (after dipyridamole infusion) was significantly impaired (1.7 ± 0.08) compared with normal subjects (2.7 ± 0.04; p <0.05). Furthermore, by examining [18F]fluorodeoxyglucose (18FDG) uptake, a perfusion-metabolism mismatch was observed in 24 ± 6% of the myocardium in patients with cardiomyopathy as opposed to 0% of normals (p <0.05). In patients with CAD, myocardial blood flow reserve (measured in non-stenotic arteries to non-infarcted area) was impaired in CHF patients (1.7 ± 0.06) compared to those with normal LV function (2.3 ± 0.05; p <0.05). In both groups of CHF patients, the impairment of blood flow reserve showed a significant correlation with the severity of CHF. In conclusion, myocardial blood flow reserve is impaired in patients with CHF in proportion to the degree of CHF. Metabolic studies with 18FDG further show that, in patients with idiopathic dilated cardiomyopathy and CHF, flow-metabolism mismatch is present in a substantial part of the myocardium, suggesting a pathogenetic role for ischemia.
Journal of Cardiovascular Pharmacology 08/1998; 32:S46-S51. · 2.29 Impact Factor
